Alpine Woods Capital Investors LLC Sells 3,561 Shares of Amgen Inc. (NASDAQ:AMGN)

Alpine Woods Capital Investors LLC cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 10.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,471 shares of the medical research company’s stock after selling 3,561 shares during the quarter. Amgen makes up about 1.5% of Alpine Woods Capital Investors LLC’s investment portfolio, making the stock its 15th biggest position. Alpine Woods Capital Investors LLC’s holdings in Amgen were worth $7,681,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in AMGN. Centricity Wealth Management LLC bought a new stake in shares of Amgen in the fourth quarter worth about $25,000. Legacy Investment Solutions LLC bought a new stake in shares of Amgen in the third quarter worth about $29,000. Synergy Investment Management LLC bought a new stake in shares of Amgen in the fourth quarter worth about $34,000. Atala Financial Inc bought a new stake in shares of Amgen in the fourth quarter worth about $34,000. Finally, Heck Capital Advisors LLC bought a new stake in shares of Amgen in the fourth quarter worth about $36,000. 76.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms recently commented on AMGN. Deutsche Bank Aktiengesellschaft dropped their price target on Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Johnson Rice set a $294.00 price target on Amgen in a research report on Wednesday, March 5th. Piper Sandler lifted their price target on Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Wolfe Research began coverage on Amgen in a research report on Friday, November 15th. They issued a “peer perform” rating for the company. Finally, Piper Sandler Companies reiterated an “overweight” rating and issued a $310.00 price target on shares of Amgen in a research report on Thursday, January 2nd. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $314.04.

Amgen Stock Up 0.0 %

Shares of NASDAQ AMGN opened at $312.64 on Friday. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The firm has a market capitalization of $167.95 billion, a price-to-earnings ratio of 41.41, a PEG ratio of 2.63 and a beta of 0.53. The stock has a 50 day moving average price of $290.77 and a 200 day moving average price of $299.61. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a yield of 3.05%. The ex-dividend date is Friday, May 16th. Amgen’s dividend payout ratio (DPR) is 126.09%.

Insider Buying and Selling

In related news, EVP Jonathan P. Graham sold 25,045 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the completion of the transaction, the executive vice president now owns 28,987 shares of the company’s stock, valued at $8,496,669.44. The trade was a 46.35 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock valued at $20,644,335 over the last 90 days. Corporate insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.